Levothyroxine formulations [Design Issues]

posted by drcampos  – Brazil, 2007-04-24 06:46 (6537 d 10:59 ago) – Posting: # 689
Views: 9,911

Dear All,

I would like to evaluate the disposition of lower dosages of levothyroxine formulations, i.e 12,5 mg and 37.5 mg (new formulations). Considering the FDA Guidance it is necessary a dose of 600 mcg for avoinding baseline effect. So, the problem is the dose (48 tablets x 12.5 mcg = 600 mcg). Does someone have experience with these studies?

Regards,

Daniel

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,666 registered users;
24 visitors (0 registered, 24 guests [including 9 identified bots]).
Forum time: 16:46 CET (Europe/Vienna)

There are only two kinds of scholars;
those who love ideas and those who hate them.    Emile Chartier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5